OUR TECHNOLOGY
Targeting the Wiskott-Aldrich-Syndrome Protein
BIMINI’s approach is based on proprietary technology that targets the Wiskott-Aldrich-Syndrome Protein (WASp), an actin nucleation related protein expressed exclusively in hematopoietic cells. WASP modulation has shown to deliver a potent anti-cancer effect.
We have a proprietary portfolio of small molecule WASP modulators (agonists and antagonists), including a proprietory WASP agonist (BM-011 – licensed from the Institute of Oncology Research in Switzerland) that is currently in the pre-clinical stage and is demonstrating potent activity in various lymphomas.
Our Team
BIMINI Biotech combines young ambitious entrepreneurs with scientific key-opinion-leaders and seasoned business experts
Digvijay Gahtory PhD
CEO
Maurits van den Nieuwboer PhD
COO
Stephen Croke PhD
Lead R&D Scientist
Prof. Francesco Bertoni PhD
Scientific advisor
Prof. Nathaniel Martin
Advisor Chemistry
Henk Viëtor PhD, MD
Advisor BD
Prof. Marc Peeters PhD
Advisor Clinical
Peter Maas
Advisor MedChem
Carine van den Brink
Advisor Legal
Prof. Ger Strous PhD
Advisor Cell Biology
Ernst Elhorst
Advisor Licensing
Latest News
Keep up to date with the latests progression and achievement of BIMINI Biotech.
BIMINI welcomes Prof. Nathaniel Martin as advisor chemistry
BIMINI Biotech is happy to have Prof. Nathaniel Martin join the team as an advisor on chemistry, supporting the lead optimization. Prof. Martin is Professor of Biological Chemistry Institute of[…]
Read more
BIMINI Biotech’s MIT Feasibility grant AUTO-WASP awarded
BIMINI Biotech has received a MIT feasibility grant (€20.000) for the AUTO-WASP project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In[…]
Read more
BIMINI Biotech closes new seed round with Libertatis Ergo Holding for the development of first-in-class therapeutics
Leiden, 29 June 2023 – BIMINI Biotech, an innovative Leiden-based therapeutics start-up that develops novel therapeutics for hematological cancers, raised an additional investment of €250,000 from lead investor Libertatis Ergo[…]
Read moreContact us
Please contact us at info@biminibiotech.nl
De contactformulier wordt hier getoond. Voor het activeren moet je de parameter ”shortcode contactformulier” instellen van het Aanpassing menu.